Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
A Unique Roadblock for Pfizer’s Osteoarthritis Drug
We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?
Bone Fractures Expected to Contribute to Growth of Orthopedic Implant Market
Minnesota-based orthopedics startup Dgimed Ortho is seeking to raise $2 million for its bone-fracture system.
A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Annual Costs of Dementia Care Exceed GDP, New Report Says
If dementia care were a company, it would be the world’s largest in terms of annual revenue, surpassing even Wal-Mart.
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Guiding Life Sciences Companies Along the Path to Success
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.
